Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

INSIDE INFORMATION ANNOUNCEMENT ON APPROVAL OF THE PROPOSED ISSUE OF A SHARES BY THE LISTING COMMITTEE OF SCI-TECH BOARD OF THE SHANGHAI STOCK EXCHANGE

This announcement is made by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements dated March 6, 2023, March 15, 2023, June 20, 2023 and September 17, 2025 and the circular dated March 31, 2023 of the Company containing, among other things, related matters of the Proposed Issue of A Shares and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. Unless otherwise defined, capitalized terms used in this announcement shall have the meanings as defined in the above announcements and circular.

The Board of Directors hereby announces that the 38th review meeting of the Listing Committee for the Sci-Tech Board of the Shanghai Stock Exchange in 2025 (the "**Meeting**") was held on September 24, 2025. In accordance with the review results of the Meeting, the Proposed Issue of A Shares and listing on the Sci-Tech Board of the Shanghai Stock Exchange by the Company has been approved by the Listing Committee for the Sci-Tech Board of the Shanghai Stock Exchange.

As the Proposed Issue of A Shares is subject to certain conditions precedent, it may or may not be completed. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the H shares of the Company. Further announcement(s) regarding the details and developments of the Proposed Issue of A Shares will be made by the Company as and when appropriate. This announcement appears for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, September 24, 2025

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.